Extended Data Fig. 1: Anti-tumour activity of double immune checkpoint blockade on B16-OVA-derived tumours on TNF blockade.
From: Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
a, Schematic representation of experiments. Experiments were performed as in Fig. 2a, but on mice bearing B16-OVA-derived tumours, treated in different groups. b, Overall survival of treatment groups. The numbers of biologically independent mice are indicated in c. P values were calculated using a two-sided log-rank test. c, Individual follow-up of tumour size, depicting the fraction of mice that completely rejected their tumours. One representative experiment out of two is shown.
